There was no statistically significant difference in the numbers of premenopausal patients with excess levels of E2, progesterone, testosterone or lower levels of FSH and LH between type 1 (n = 59) and type 2 (n = 8) endometrial cancer (p > 0.419). Here, BRD2 is linked to endometrial cancer.